<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01543906</url>
  </required_header>
  <id_info>
    <org_study_id>RET RP 01</org_study_id>
    <nct_id>NCT01543906</nct_id>
  </id_info>
  <brief_title>Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)</brief_title>
  <official_title>An Open-Label, Phase 1b, Safety/Proof-of-Concept Study to Evaluate the Effects of Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>QLT Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>QLT Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

        -  To evaluate whether 7-day treatment with oral QLT091001 can improve visual function in
           RP subjects with an autosomal dominant mutation in RPE65.

        -  To evaluate duration of visual function improvement (if observed) in RP subjects with an
           autosomal dominant mutation in RPE65 after 7-day treatment with oral QLT091001.

        -  To evaluate the safety of oral QLT091001 administered once daily for 7 days in RP
           subjects with an autosomal dominant mutation in RPE65.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual field</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be assessed by evaluating the following: adverse events, clinical laboratory results, ECG's and vital signs</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Retinitis Pigmentosa (RP)</condition>
  <arm_group>
    <arm_group_label>QLT091001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral QLT091001 administered once daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QLT091001</intervention_name>
    <description>oral QLT091001 administered once daily for 7 days</description>
    <arm_group_label>QLT091001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will have RP caused by an autosomal dominant mutation in RPE65, as diagnosed
             by an ocular geneticist or ophthalmologist.

          -  Subjects who have a best-corrected standard ETDRS visual acuity of 3 letters or better
             (20/800 Snellen equivalent) or visible photoreceptor outer segments on OCT/FAF.

        Exclusion Criteria:

          -  Subjects with any clinically important abnormal physical finding at Screening.

          -  Subjects who have taken any prescription or investigational oral retinoid medication
             (e.g., Accutane/Roaccutane® or Soriatane/Neotigason®) within 6 months of Day 0 and
             subjects who did not tolerate their previous oral retinoid medication will be excluded
             regardless of the time of last exposure.

          -  Subjects with a history of diabetes or chronic hyperlipidemia, hepatitis,
             pancreatitis, or cirrhosis.

          -  Subjects who have taken any supplements containing ≥10,000 IU vitamin A within 60 days
             of Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sushanta Mallick</last_name>
    <role>Study Director</role>
    <affiliation>QLT Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montreal Children's Hospital, McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Eye and Ear Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Ireland</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2012</study_first_submitted>
  <study_first_submitted_qc>March 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2012</study_first_posted>
  <last_update_submitted>December 11, 2014</last_update_submitted>
  <last_update_submitted_qc>December 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Cone-Rod Dystrophies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinol acetate</mesh_term>
    <mesh_term>Vitamin A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

